Jerry Dvonch
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jerry Dvonch
Earlier roles on record: CFO at Sonoma Pharmaceuticals, Inc. (SNOA) until November 18, 2022. Sonoma Pharmaceuticals, Inc. reported in an 8-K filed April 13, 2023 that Jerry Dvonch was appointed interim Chief Financial Officer, effective April 7, 2023. Sonoma Pharmaceuticals, Inc. reported in an 8-K filed October 7, 2022 that Jerry Dvonch resigned as Chief Financial Officer, effective November 18, 2022. The proxy statement of Sonoma Pharmaceuticals, Inc. reports total compensation of $422,679 for Jerry Dvonch in fiscal 2026, including a base salary of $240,000. Disclosed compensation is on record for 4 fiscal years.
“Effective April 7, 2023, Chad White resigned as our Chief Financial Officer, and our Board of Directors appointed Jerry Dvonch as our interim Chief Financial Officer.”
“We accepted the resignation of Mr. Dvonch as Chief Financial Officer effective November 18, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2020-09-08–2022-11-18
-
Start not stated–2022-11-18
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2026 | Sonoma Pharmaceuticals, Inc. (SNOA) | Chief Financial Officer | $240,000 | $422,679 |
| 2025 | Sonoma Pharmaceuticals, Inc. (SNOA) | Chief Financial Officer | $240,000 | $357,527 |
| 2024 | Sonoma Pharmaceuticals, Inc. (SNOA) | Chief Financial Officer | $60,000 | $307,458 |
| 2022 | Sonoma Pharmaceuticals, Inc. (SNOA) | Interim Chief Financial Officer | $200,000 | $427,000 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.